A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Trial Identifier: 213357-COHORT-C
Sponsor: Tesaro
Start Date: April 2022
Primary Completion Date: June 2024
Study Completion Date: March 2025
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Ontario Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec Montreal, Quebec, Canada, H4A 3J1
Canada, Quebec Montreal, Quebec, Canada, H2X 0A9
Spain, ES A Coruña, ES, Spain, 15006
Spain, ES Madrid, ES, Spain, 28223
Spain, ES Madrid, ES, Spain, 28033
Spain, ES Madrid, ES, Spain, 28050
Spain, ES Madrid, ES, Spain, 28027
Spain, ES Málaga, ES, Spain, 29001
Spain, ES Pamplona, ES, Spain, 31008
US, California San Francisco, California, US, 94115
US, FL Miami, FL, US, 33136
US, FL Tampa, FL, US, 33606
US, MA Boston, MA, US, 02114
US, ME Scarborough, ME, US, 04074
US, MO St Louis, MO, US, 63141
US, New York New York, US, 77030
US, NY NY, US, 10029
US, NY Rochester, NY, US, 14642
US, SD Sioux Falls, SD, US, 57105
US, WA Seattle, WA, US, 98104